Tissue Regenix Group PLC DermaPure to be Showcased in Nine Posters at SAWC

TIDMTRX

Tissue Regenix Group PLC

03 February 2016

Tissue Regenix Group plc

("Tissue Regenix or "The Group")

DermaPure(R) selected to feature nine poster presentations at Woundcare Symposium

York, 03 February 2016 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix") or ("The Group") the regenerative medical devices company, is pleased to announce Tissue Regenix Wound Care, Inc. will display nine poster presentations at the Symposium on Advanced Wound Care (SAWC) Spring conference to be held in Atlanta, Georgia, April 13-17.

Focussed on the Groups first commercialised product DermaPure, the posters have been written by various key opinion leaders including Clinicians, Clinical Affairs and researchers. They were selected and approved by a peer review committee and will focus on areas such as; clinical efficacy in various types of wounds, pain reduction, a retrospective analysis of clinical outcomes and an analysis of DermaPure's Extracellular Matrix.

DermaPure was released to the US market in 2014, and has been used to treat wounds from diabetic or pressure ulcers through to Frostbite. The Medicare 'Q' code became effective January 2015 allowing clinics to be reimbursed for the product and is now available to c.65% of Medicare beneficiaries. Tissue Regenix announced in January 2016 that sales of DermaPure had surpassed $1m since launch.

Greg Bila, President Tissue Regenix Wound Care, Inc. commented "We are extremely proud of how DermaPure has performed within a competitive marketplace since it was launched in 2014. Having nine posters chosen by a peer review committee to appear at SAWC, I think, illustrates a deeper understanding and appreciation of the dCELL(R) technology platform, and the difference that a product like DermaPure can make to patient treatment and recovery. We look forward to discussing this further at this year's spring SAWC, and I would like to extend my thanks to all who have contributed to these presentations"

Poster titles

 
 Author(s)                       Title 
 Constantine Demou DPM,          Use of Regenerative, Decellularized 
  Brendan McCarty DPM Jennifer    Skin Replacement*on Severe Acute Diabetic 
  Michael DPM                     Foot Wounds Involving Exposed Bone 
                                  and Tendon: A Three Case Series 
 Valarie Muehlenbruch,           The Use of a Regenerative, Decellularized 
  RN, Kate Biasiolli, RN,         Skin Replacement* to Close Partial 
  Patti Gary, RN, CWCN            Foot Amputation Wounds and Contribute 
                                  to Diabetic Limb Salvage 
 Jake Lambert, MD                The Effect of Pain in Patients Treated 
                                  with Decellularized Human Dermal Grafts 
 Howard Kimmel DPM, Arthur       The Use of a Decellularized Dermal 
  Tallis DPM                      Allograft in the Treatment of Chronic 
                                  Venous Leg Ulcers 
 HowardKimmel DPM                Retrospective Analysis of Utilizing 
                                  A Decellularized Dermal Allograft to 
                                  Treat Chronic Wounds 
 Anna LeMoine, BSc, MSC,         Maintenance of Key Extracellular Matrix 
  PhD; Vassilis Vayianos,         Components in a Decellularised Human 
  BSc, MSc, PhD and Patti         Dermis Product* 
  Gary, RN, CWCN 
 Jaminelli Banks, DPM,           Decellularized Human Dermis* Drives 
  Robert Frykberg, DPM            Rapid Surface Area Reduction and Closure 
                                  for Neuropathic Ulcer 
 Michael Desvigne, MD            Unique Combined Application of an Ovine 
                                  Collagen Dressing with an Intact Extracellular 
                                  Matrix (CECM) with a Decellularized 
                                  Dermis to Assist in Closure of a Radiated 
                                  Lower Extremity Wound 
 Michael Desvigne, MD            Optimizing Wound Bed for Application 
                                  of Cellular Tissue Based Products Using 
                                  an Ovine Collagen Dressing with an 
                                  Intact Extracellular Matrix

For more information:

 
 Tissue Regenix Group plc                                  Tel: 01904 567 
  Caitlin Pearson - Corporate Communications Officer                  609 
 Jefferies International Ltd                           Tel: 020 7029 8000 
  Simon Hardy / Harry Nicholas 
 Tulchan Communications                                Tel: 020 7353 4200 
  James Macey-White / Matt Low

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL(R) technology platform.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAPAAEDPKEFF

(END) Dow Jones Newswires

February 03, 2016 02:00 ET (07:00 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024